JAMA Dermatology

<jats:sec id="ab-dcs240009-4"><jats:title>Importance</jats:title><jats:p>The results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients with hair loss, but larger trials and standardized guidelines are lacking.</jats:p></jats:sec><jats:sec id="ab-dcs240009-5"><jats:title>Objective</jats:title><jats:p>To create an expert consensus statement for LDOM prescribing for patients with hair loss.</jats:p></jats:sec><jats:sec id="ab-dcs240009-6"><jats:title>Evidence Review</jats:title><jats:p>The current literature on the pharmacological properties, adverse effect profile, and use of LDOM for patients with hair loss was reviewed. Topics of interest were identified, and a modified Delphi consensus process was created. A total of 43 hair loss specialist dermatologists from 12 countries participated in a modified Delphi process. Consensus was reached if at least 70% agreed or strongly agreed on a 5-point Likert scale.</jats:p></jats:sec><jats:sec id="ab-dcs240009-7"><jats:title>Findings</jats:title><jats:p>Over 4 survey rounds, 180 items in the first round, 121 items in the second round, 16 items in the third round, and 11 items in the fourth round were considered and revised. A total of 76 items achieved consensus including diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM compared to topical minoxidil, dosing for adults (18 years and older) and adolescents (aged 12 to 17 years), contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation. Pediatric use and dosing items for children younger than 12 years, and LDOM titration protocols fell short of consensus.</jats:p></jats:sec><jats:sec id="ab-dcs240009-8"><jats:title>Conclusions and Relevance</jats:title><jats:p>This international expert consensus statement regarding the off-label prescribing of LDOM for patients with hair loss can help guide clinical practice until more data emerge. Hair loss experts with experience treating pediatric patients were underrepresented on this expert panel. Future research should investigate best practices for LDOM use in pediatric patients. Other critical topics for further investigation include the comparative efficacy of topical minoxidil vs oral minoxidil, the safety of oral minoxidil for patients with a history of allergic contact dermatitis to topical minoxidil, the long-term safety of LDOM, and the use of other off-label forms of minoxidil, such as compounded formulations of oral minoxidil and sublingual minoxidil. As additional evidence-based data emerge, these recommendations should be updated.</jats:p></jats:sec>

Hair loss: common causes and treatment.

Am Fam Physician

Treatment of hair loss.

N Engl J Med

Diagnosis and treatment of nonscarring hair loss in primary care in 2021.

JAMA

Topical and oral minoxidil for hair disorders in pediatric patients: what do we know so far?

Dermatol Ther

Hair disorders in cancer survivors.

J Am Acad Dermatol

Minoxidil: a comprehensive review.

J Dermatolog Treat

Oral minoxidil treatment for hair loss: a review of efficacy and safety.

Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients.

Safety of low-dose oral minoxidil treatment for hair loss: a systematic review and pooled-analysis of individual patient data.

Prospective cardiovascular evaluation with 24-hour Holter and 24-hour ambulatory blood pressure monitoring in men using 5-mg oral minoxidil for androgenetic alopecia.

Combination tofacitinib and oral minoxidil treatment for severe alopecia areata.

Systemic minoxidil for hair disorders in pediatric patients: a safety and tolerability review.

Int J Dermatol

Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: a descriptive study.

Treatment for central centrifugal cicatricial alopecia—Delphi consensus recommendations.

Survey of dermatology practitioners’ opinions and prescribing habits of oral minoxidil for the treatment of androgenetic alopecia.

J Drugs Dermatol

Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.

Treatment of chronic telogen effluvium with oral minoxidil: a retrospective study.

F1000Res

Low-dose oral minoxidil improves hair density in traction alopecia.

Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: a retrospective study.

Low-dose oral minoxidil improves hair length and global hair density in short anagen syndrome.

Trichorrhexis nodosa improving with oral minoxidil: a case report.

Clin Exp Dermatol

Serious complication of low-dose oral minoxidil for hair loss.

JAAD Case Rep

Pericardial, pleural effusion and anasarca: a rare complication of low-dose oral minoxidil for hair loss.

The Delphi technique: myths and realities.

J Adv Nurs

SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.

BMJ Qual Saf

The REDCap consortium: building an international community of software platform partners.

J Biomed Inform

The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata.

The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata.

A global eDelphi exercise to identify core domains and domain items for the development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS).

JAMA Dermatol

The Alopecia Areata Severity and Morbidity Index (ASAMI) study: results from a global expert consensus exercise on determinants of alopecia areata severity.

The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: an initiative to harmonize data collection across national atopic eczema photo- and systemic therapy registries.

J Invest Dermatol

TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries.

Trials

TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo- and systemic therapy registries.

Br J Dermatol

How safe is prescribing oral minoxidil in patients allergic to topical minoxidil?

The results of small studies suggest that off-label use of low-dose oral minoxidil (LDOM) may be safe and effective for patients with hair loss, but larger trials and standardized guidelines are lacking.
To create an expert consensus statement for LDOM prescribing for patients with hair loss.
The current literature on the pharmacological properties, adverse effect profile, and use of LDOM for patients with hair loss was reviewed. Topics of interest were identified, and a modified Delphi consensus process was created. A total of 43 hair loss specialist dermatologists from 12 countries participated in a modified Delphi process. Consensus was reached if at least 70% agreed or strongly agreed on a 5-point Likert scale.
Over 4 survey rounds, 180 items in the first round, 121 items in the second round, 16 items in the third round, and 11 items in the fourth round were considered and revised. A total of 76 items achieved consensus including diagnoses for which LDOM may provide direct or supportive benefit, indications for LDOM compared to topical minoxidil, dosing for adults (18 years and older) and adolescents (aged 12 to 17 years), contraindications, precautions, baseline evaluation, monitoring, adjunctive therapy, and specialty consultation. Pediatric use and dosing items for children younger than 12 years, and LDOM titration protocols fell short of consensus.
This international expert consensus statement regarding the off-label prescribing of LDOM for patients with hair loss can help guide clinical practice until more data emerge. Hair loss experts with experience treating pediatric patients were underrepresented on this expert panel. Future research should investigate best practices for LDOM use in pediatric patients. Other critical topics for further investigation include the comparative efficacy of topical minoxidil vs oral minoxidil, the safety of oral minoxidil for patients with a history of allergic contact dermatitis to topical minoxidil, the long-term safety of LDOM, and the use of other off-label forms of minoxidil, such as compounded formulations of oral minoxidil and sublingual minoxidil. As additional evidence-based data emerge, these recommendations should be updated.

Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement.

Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss

Papers